-
05.12.2022 | Are Antibiotics Doomed? David Hyun & Erin Duffy on the Crisis No One Talks About
In 2019, about 1.27M people died directly due to antimicrobial resistance - significantly more than from Covid in two years. When we lose antibiotics, we will be in a different world. Joint and organ replacement, cancer treatments and many other medical procedures will be a thing of the past. Terrence McNally talks about the growing dangers of antibiotic resistance and the lack of new drugs with David Hyun, MD, who directs the Antibiotic Resistance Project at the Pew Charitable Trust, and Erin Duffy, Chief of R&D at CARB-X.
-
04.27.2022 | ENTASIS THERAPEUTICS HOLDINGS INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
MARKET SCREENER | The report includes a discussion and analysis of Entasis’ financial condition and results of operations.
-
04.20.2022 | SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001
BENZIGA | SNIPR BIOME ApS, a leading CRISPR and microbiome gene therapy biotechnology company, announced dosing of the first human subjects in its phase 1 clinical trial with SNIPR001, an orally administered CRISPR-based therapeutic.
-
04.20.2022 | Clinical update: SNIPR BIOME doses first human subjects with CRISPR-based antibiotic
CRISPR MEDICINE NEWS | SNIPR BIOME announced this morning that it has dosed the first participants in a clinical trial for SNIPR0001, an orally administered CRISPR-based therapeutic designed to reduce E. coli colonization in the gut to prevent blood infections in patients with cancer.
-
04.18.2022 | An episode about CARB-X with Erin Duffy and Kevin Outterson
PROGRESS, POTENTIAL & POSSIBILITIES PODCAST | Host Ira Pastor speaks with Erin Duffy and Kevin Outterson about how and why CARB-X supports innovative antibiotics vaccines and diagnostics to treat, prevent and diagnose AMR bacterial infections for a global population.
-
04.13.2022 | Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results
BAKERSFIELD | Vedanta Biosciences, a leading clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, today announced the publication in the journal Cell Host & Microbe of the results from a Phase 1a/1b study evaluating the safety, tolerability, and colonization dynamics of VE303 in healthy adults. VE303 is a potential first-in-class defined bacterial consortium candidate for the prevention of recurrent Clostridium difficile infection (CDI). The company will also share three research updates across its VE303 and VE202 (for inflammatory bowel disease) programs in podium presentations at Digestive Disease Week in May 2022.
-
04.11.2022 | Day Zero Diagnostics Announces the Launch of Day Zero Lab Services
CISION PRWEB | Day Zero Diagnostics, Inc., an infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, today announced the launch of Day Zero Lab Services focused on providing hospitals with services focused on whole-genome sequencing-based assays.
-
04.07.2022 | Lumen Bioscience: Spirulina-based platform enables rapid, low-cost development of oral biologics
BIOPHARMA-REPORTER | Researchers at Lumen Bioscience report in Nature Biotechnology genetic engineering methods to highly express bioactive proteins in spirulina using large-scale cultivation and processing methods appropriate for biopharmaceutical manufacturing.
-
04.05.2022 | Boston University Led CARB-X Grants Clarametyx Biosciences an Additional $3.89 Million in Funding to Accelerate Anti-Biofilm Therapy for Bacterial Infections TrialSite Staff April 5, 2022
TrialSite News | Clarametyx Biosciences, a preclinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter serious infections associated with biofilm, announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), has awarded the company an additional $3.89 million in option funding. The grant will be used toward advancing the development of CMTX-101, a novel anti-biofilm therapy with a first targeted indication for moderate-to-severe pneumonia.
-
04.04.2022 | Pharma’s ambitious new antibiotic venture fund makes its first investments
STAT | The AMR Action Fund is providing an undisclosed portion of its $1 billion in initial backing — much of which comes from several of the world’s largest drug manufacturers — toward Venatorx Pharmaceuticals and Adaptive Phage Therapeutics. The two privately held companies are taking a different approach toward developing therapies that can fight drug-resistant infections.
-
04.04.2022 | Venatorx Pharmaceuticals Raises Series C Financing Led by the AMR Action Fund
HERALD CHRONICLE | Venatorx Pharmaceuticals, Inc., a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, today announced that it sold shares of its Series C Preferred Stock in a financing led by the AMR Action Fund with participation from existing investors including Abingworth.
-
03.24.2022 | Integrated Biotherapeutics Awarded $3.55M Grant to Study Immune Correlates of Protection Against Recurrent Staphylococcal Infection
WFMZ | Study is expected to provide insights into mechanisms of protection against staph infection. IBT and its subsidiary Integrated BioTherapeutic Vaccines (IBV) are developing IBT-V02, a novel vaccine for S. aureus infections with support from CARB-X and Novo Holdings. IBT-V02 will enter Phase 1 clinical trial this year.
-
03.21.2022 | Superfood spirulina harnessed as biomanufacturing engine
HEALTH TECH WORLD | A common food source has been converted into a biomanufacturing platform that enables mass production of biologic drugs for common diseases that currently lack effective treatments. Researchers at Lumen Bioscience have pioneered genetic engineering methods to highly express bioactive proteins in spirulina using large-scale cultivation and processing methods appropriate for biopharmaceutical manufacturing.
-
03.03.2022 | Spexis achieves first CARB-X milestone for its thanatin derivatives program and receives funding of up to USD 1.9 million to initiate lead optimization
BIOSPACE | Spexis has received this award based upon the achievement of technical milestones within the previously announced CARB-X collaboration for this program. The award will support the continuation of the "thanatin derivatives program" belonging to Spexis' novel Outer Membrane Protein Targeting Antibiotic (OMPTA) class of antibiotics to potentially treat life-threatening infections caused by difficult-to-treat Gram-negative bacteria.
-
03.02.2022 | Combating AMR with Diagnostics
BIOSPECTRUM | Early diagnosis plays a significant role in effective management of AMR. Faster and accurate diagnostic tests enable identification and pathogen identification so patients can be treated with the most appropriate drug quickly. This prevents antibiotic misuse and overuse, and can play a vital role in timely interventions to improve patient outcomes and reduce the spread of resistance.
-
02.28.2022 | The Global Burden of AMR
INFECTIOUS CONVERSATIONS PODCAST | Episode 1 features Kevin Outterson (CARB-X), Dr. Helen Boucher (Tufts University School of Medicine), and Mary Booth Dwight (Cystic Fibrosis Foundation) who discuss the global burden of AMR.
-
02.17.2022 | Report highlights ‘fragile and failing’ antibiotic pipeline
CIDRAP | The report on antibacterial innovation from the Biotechnology Innovation Organization (BIO) concludes that the breadth and the novelty of the clinical antibacterial pipeline is insufficient to meet the growing threat of antibiotic-resistant pathogens.
-
02.16.2022 | The hidden epidemic
VOX | Antibiotic resistance is approaching a crisis point, and the world needs to act
-
02.05.2022 | Antibiotic Resistant Bacteria, A Growing Global Threat
HealthCall LIVE | Lee Kelso talks with Kevin Outterson from CARB-X about the risk of bacteria that antibiotics can’t kill and the search for effective drugs.
-
02.01.2022 | AMR Action Fund Appoints Scientific Advisory Board
AMR ACTION FUND | Members will play a vital role in evaluating potential investments into clinical-stage companies developing urgently needed antibiotics
-
01.27.2022 | The World’s Next Big Health Emergency Is Already Here
BLOOMBERG OPINION | Covid-19 has claimed nearly 6 million lives. Antimicrobial resistance may claim 10 million annually by 2050 — and that figure is starting to look low.
-
01.27.2022 | AMR Action Fund head aims to boost innovation, funds for new antibiotics
CIDRAP | The science is not the issue, experts say. The big problem is the lack of a viable market for new antibiotics, one that reimburses antibiotic developers for the public health value of their product.
-
01.27.2022 | RTP’s Locus Biosciences grows as it tackles issue of drug-resistant bacteria
THE NEWS & OBSERVER | Locus Biosciences is expecting more growth in 2022, as the gene-editing company strives to provide alternatives to the pressing issue of drug-resistant bacteria.
-
01.26.2022 | Drug-Resistant Superbugs Are Causing More Deaths: What’s Being Done?
HEALTHLINE | For years, scientists have been sounding the alarm about how so-called superbugs can be life threatening. Now, a new study outlines just how life threatening that drug resistance is when it comes to antibiotics, or what scientists call antimicrobial resistance.
-
01.24.2022 | AMR May Be the ‘Next Pandemic’
MEDPAGE TODAY | Feds lead investment in antimicrobial resistance, but more private help is needed, BARDA says
Toggle navigation